AIM ImmunoTech Announced It Was Granted Patent No. 2,0832,813 Covering Ampligen For Use In Treatment Of Post-COVID Condition Of Fatigue
AIM ImmunoTech Announced It Was Granted Patent No. 2,0832,813 Covering Ampligen For Use In Treatment Of Post-COVID Condition Of Fatigue
AIM ImmunoTech宣佈獲得專利號2,0832,813，涵蓋Ampligen用於治療後COVID疲勞症狀。
AIM ImmunoTech Announced It Was Granted Patent No. 2,0832,813 Covering Ampligen For Use In Treatment Of Post-COVID Condition Of Fatigue
AIM ImmunoTech宣佈獲得專利號2,0832,813，涵蓋Ampligen用於治療後COVID疲勞症狀。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。